US Stock MarketDetailed Quotes

CCCC C4 Therapeutics

Watchlist
  • 2.140
  • +0.060+2.88%
Close Mar 19 16:00 ET
  • 2.140
  • 0.0000.00%
Post 20:01 ET
151.92MMarket Cap-1.41P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jan 14 20:00
    NEWS
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
    Tuesday, 14th January at 7:00 am
    Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma
    CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monoth...
    This_Guy
    This_Guy
    Dec 9, 2024 07:20
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    Positive
    36% overall response rate and 45% clinical benefit rate achieved in MM at highest dose level
    38% overall response rate in NHL across all subtypes
    44% overall response rate in PTCL specifically
    No treatment emergent adverse events leading to dose reduction
    Well-tolerated safety profile...
    Jaguar8
    Jaguar8
    Dec 9, 2024 06:21
    NEWS SUNDAY 12/8
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical b...
    Trytosaveabit
    Trytosaveabit
    Dec 9, 2024 05:59
    Watching Monday/week 12/9/24 Data released
    $C4 Therapeutics (CCCC.US)$ In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
    Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Le...
Read more

Trending Stocks

U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Abits
ABTS
3.850
TeraWulf
WULF
3.300
Bitdeer Technologies
BTDR
10.570
4
IREN Ltd
IREN
7.200
5
Hut 8
HUT
12.930
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
FOMC Press Conference, March 19, 2025
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.